RENALYTIX AI PLC-ADR (RNLX)
US75973T1016 - ADR
We assign a fundamental rating of 2 out of 10 to RNLX. RNLX was compared to 37 industry peers in the Health Care Technology industry. RNLX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RNLX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RNLX had negative earnings in the past year.
In the past year RNLX has reported a negative cash flow from operations.
In the past 5 years RNLX always reported negative net income.
In the past 5 years RNLX always reported negative operating cash flow.
1.2 Ratios
RNLX has a worse Return On Assets (-109.75%) than 89.19% of its industry peers.
RNLX has a worse Return On Equity (-250.48%) than 83.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -109.75% | ||
| ROE | -250.48% | ||
| ROIC | N/A |
ROA(3y)-76.55%
ROA(5y)-54.96%
ROE(3y)-138.17%
ROE(5y)-92.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 20.60%, RNLX is doing worse than 86.49% of the companies in the same industry.
RNLX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RNLX has more shares outstanding
The number of shares outstanding for RNLX has been increased compared to 5 years ago.
RNLX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.75, we must say that RNLX is in the distress zone and has some risk of bankruptcy.
RNLX has a Altman-Z score of -5.75. This is amonst the worse of the industry: RNLX underperforms 83.78% of its industry peers.
A Debt/Equity ratio of 0.41 indicates that RNLX is not too dependend on debt financing.
The Debt to Equity ratio of RNLX (0.41) is worse than 62.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.75 |
ROIC/WACCN/A
WACC6.65%
2.3 Liquidity
RNLX has a Current Ratio of 1.76. This is a normal value and indicates that RNLX is financially healthy and should not expect problems in meeting its short term obligations.
RNLX has a Current ratio (1.76) which is in line with its industry peers.
RNLX has a Quick Ratio of 1.71. This is a normal value and indicates that RNLX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of RNLX (1.71) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 27.23% over the past year.
RNLX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.58%.
EPS 1Y (TTM)27.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.99%
Revenue 1Y (TTM)14.58%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.35%
3.2 Future
Based on estimates for the next years, RNLX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.35% on average per year.
RNLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 73.89% yearly.
EPS Next Y59.3%
EPS Next 2Y32.95%
EPS Next 3Y21.35%
EPS Next 5YN/A
Revenue Next Year39.85%
Revenue Next 2Y68.91%
Revenue Next 3Y73.89%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RNLX. In the last year negative earnings were reported.
Also next year RNLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RNLX's earnings are expected to grow with 21.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.95%
EPS Next 3Y21.35%
5. Dividend
5.1 Amount
No dividends for RNLX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RENALYTIX AI PLC-ADR
NASDAQ:RNLX (10/7/2024, 8:16:27 PM)
After market: 0.13 -0.08 (-37.23%)0.2071
+0.01 (+5.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners4.26%
Inst Owner Change5.6%
Ins Owners6.06%
Ins Owner Change265.95%
Market Cap17.18M
Analysts84
Price Target2.67 (1189.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)30.74%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.05 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.93 | ||
| P/tB | 2.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.04
BVpS0.22
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -109.75% | ||
| ROE | -250.48% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.6% | ||
| FCFM | N/A |
ROA(3y)-76.55%
ROA(5y)-54.96%
ROE(3y)-138.17%
ROE(5y)-92.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z | -5.75 |
F-Score2
WACC6.65%
ROIC/WACCN/A
Cap/Depr(3y)34.78%
Cap/Depr(5y)392%
Cap/Sales(3y)44.23%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.99%
EPS Next Y59.3%
EPS Next 2Y32.95%
EPS Next 3Y21.35%
EPS Next 5YN/A
Revenue 1Y (TTM)14.58%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-68.35%
Revenue Next Year39.85%
Revenue Next 2Y68.91%
Revenue Next 3Y73.89%
Revenue Next 5YN/A
EBIT growth 1Y26.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.82%
EBIT Next 3Y19.78%
EBIT Next 5YN/A
FCF growth 1Y29.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.57%
OCF growth 3YN/A
OCF growth 5YN/A